These findings not only identify novel molecular targets for the precise treatment of rosacea but also establish a theoretical framework for the development of targeted therapies, such as IRF1 inhibitors or SLC22A5 activators, thereby facilitating critical advancements in translating genetic research into clinical applications. This evidence concerns the gene SLC22A5 and rosacea.